- GlobeNewswire•yesterdayAnthera Announces Leadership Transition in Preparation of Commercialization of Sollpura and Future Development of blisibimod for IgA Nephropathy
J. Craig Thompson promoted to Chief Executive Officer and appointed to the Board of Directors Paul F. Truex appointed as Executive Chairman of the Board Dr. Christopher Henney stepped down as Chairman ...
- GlobeNewswire•yesterdayAnthera Reports Blisibimod BRIGHT-SC IgA Nephropathy Continues to Demonstrate Positive Trends in the Week 48 Analysis
Lower proteinuria in blisibimod versus placebo treated patients Changes in circulating B-cells and serum immunoglobulins consistent with BAFF inhibition. HAYWARD, Calif., Dec. 06, 2016-- Anthera Pharmaceuticals, ...
- 24/7 Wall St.•26 days ago
The U.S. presidential election is now over and markets have seemingly recovered to just below their highs but there are still some laggards.
ANTH : Summary for Anthera Pharmaceuticals, Inc. - Yahoo Finance
Anthera Pharmaceuticals, Inc. (ANTH)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Day's Range||1.63 - 2.53|
|52 Week Range||1.33 - 5.19|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.41|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|